Telomerase reverse transcriptase hTERT is an attractive target for cancer immunotherapy given its broad expression in human tumors and its demonstrated immunogenicity. Human and murine model systems demonstrate that CD8 + cytotoxic T-lymphocytes (CTL) and CD4 + helper T-lymphocytes can recognize dominant epitopes derived from TERT. CTL kill TERT-positive tumor cells of multiple histologies, although there is some disagreement regarding the level of processing and presentation of certain TERT peptides within the context of MHC class I molecules. CTL recognizing modified, low-affinity cryptic TERT epitopes have also been generated that protect against tumor challenge in a murine model. Several phase I clinical trials testing hTERT as a cancer vaccine target have shown the induction of T-cell immune responses but minimal toxicities, including bone marrow toxicity, in patients with multiple types of cancer.
Introduction
Experimental data from the past 10 years have demonstrated that tumor-associated antigens (TAA) can cause highly specific T-lymphocyte responses against cancer cells while sparing normal cells. These observations form the rationale behind the use of hTERT (human telomerase reverse transcriptase) as a potential antigen for cancer immunotherapy. The original TAA were discovered in the early 1990s from the analysis of tumor infiltrating T-lymphocytes in melanoma patients (Van Pel et al. 1995; Rosenberg 1997 ). Numerous TAA from a variety of malignancies have now been identified, suggesting that all cancers possess associated antigens that can be used to direct a specific anti-tumor T-lymphocyte response (Van Pel et al. 1995; Rosenberg 1997 Rosenberg , 2001 ; Van den Eynde and van der Bruggen 1997). Animal models have provided further validation (Gilboa 1999 ) that these TAA can function as tumor rejection antigens in vivo.
CD8 + cytotoxic T-lymphocytes (CTL) have been studied as the chief effector cell of the antigen-specific lymphocyte immune response (Van Pel et al. 1995; Van den Eynde and van der Bruggen 1997) . Antigen receptors on the surface of CTL recognize 9-10 amino acid peptides presented on the surface of tumor cells in the context of major histocompatability complex (MHC) class I molecules. Specific recognition of peptide/MHC complexes by CTL antigen receptor leads to a T-cell response of cytokine secretion and eventual target cell lysis. Proteosomal digestion of intracytoplasmic proteins, which may or may not be destined for the cell surface, generates peptide epitopes presented by MHC I molecules. Tumor antigens discovered to date are largely intracytoplasmic self-antigens that are either overexpressed or selectively expressed by tumor cells.
Problem of universal antigens
While the concept of TAA was a significant scientific breakthrough, the problem of discovering antigens that can be widely applied to various malignancies, i.e. universal TAA, has been a limitation. A factor contributing to the limited characterization of universal tumor expression has been the method of antigen discovery commonly employed. The classical approach relies upon the isolation of tumor infiltrating lymphocytes and determining antigens these CTL react against. Such methodology limits researchers to search malignancy-by-malignancy for antigens and only for tumors for which tumor infiltrating lymphocytes can be isolated. The hTERT peptides were discovered using a method of epitope deduction. Our group analyzed genes that were selectively expressed by a variety of tumor cells, and then analyzed those applicable gene products to deduce protein sequences for peptides that match known MHC binding motifs (reviewed in Schultze and Vonderheide 2001) . This method does not rely upon the presence of an anti-tumor response, therefore allowing the discovery of antigens that classical analysis could never find. Validation of these deduced epitopes occur via a series of immunological studies that have been previously reviewed (Schultze and Vonderheide 2001) .
The case for hTERT as a universal antigenselective expression and auto-immunity Criteria for universal TAA include: (i) expression by the vast majority of human cancers, (ii) presence of peptides that bind to MHC molecules, (iii) sufficient natural antigen processing by tumor cells that leads to expression of antigen-derived peptides in the groove of MHC, and (iv) recognition by T-cell repertoire in an MHC-restricted fashion. Data from the past 5 years suggest that telomerase catalytic subunit hTERT meets these criteria.
Expression of hTERT correlates best with telomerase activity, suggesting that the catalytic subunit functions as the rate-limiting component of telomerase (Harrington et al. 1997; Meyerson et al. 1997; Nakamura et al. 1997; Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998) . Telomerase maintains the telomeric ends of linear chromosomes, protecting them from degradation and end-to-end fusion . Expression of telomerase has been directly linked to human cancer development (Hahn et al. 1999a) , and without telomerase activity, cancer cells are thought to be unable to replicate beyond the limits of normal cells leading to eventual death. Therefore, even with the selective pressure of immunotherapy, malignancies should not be able to clonally select for hTERT negative cells and still maintain their prolonged cell life span. Work in cell culture demonstrates that inhibition of telomerase in telomerase-positive cells leads to tumor death without the emergence of telomerase-negative cells (Hahn et al. 1999b; Herbert et al. 1999; Zhang et al. 1999) . While not an explicit criterion for universal antigens, prevention of immune escape adds to the value of hTERT as a target for immunotherapy.
Most human cells do not have telomerase activity or hTERT expression Meyerson et al. 1997; Nakamura et al. 1997) , while the great majority of human tumor cells (>85% of human cancers) exhibit strong telomerase activity , express hTERT (Meyerson et al. 1997; Nakamura et al. 1997; Ramakrishnan et al. 1998) , and maintain the length of their telomeres (Counter et al. 1992 . Normal cells that do possess telomerase activity include CD34 + hematopoietic progenitor cells (Broccoli et al. 1995; Hiyama et al. 1995) , keratinocytes (Harle-Bachor and Boukamp 1996; Yasumoto et al. 1996) , and activated B-lymphocytes (Vonderheide et al. 1999) . Recently, primary presenescent human fibroblasts have been shown to express telomerase (Masutomi et al. 2003) , a surprising finding given that fibroblasts were previously thought to lack any telomerase activity. The presence of hTERT in some normal cells, particularly hematopoietic progenitor cells and B-cells, raises serious questions of potential auto-immune side effects of hTERT-based cancer immunotherapy. However, all experimental results to date illustrate that hTERT-specific CTL do not lyse either telomerase-positive CD34 + hematopoeitic progenitor cells -with or without cytokine activation -or activated T-lymphocytes (Vonderheide et al. 1999 (Vonderheide et al. , 2001a Minev et al. 2000) . Activated B-lymphocytes are the only cell type other than tumor cells that have shown an in vitro susceptibility to hTERT-specific CTL mediated lysis (Vonderheide et al. 1999) . The mechanisms by which CD34 + progenitor cells avoid while B-cells are prone to lysis have yet to be elucidated. Variety in antigen processing and different levels of hTERT expression are two leading hypotheses.
Processing, presentation, and recognition -the ongoing debate
Tumor cells physiologically express peptides in the groove of MHC class I molecules on the cell surface (a process known as natural processing and presentation), where they can be recognized by CTL induced, for example, by vaccination with these same peptides. This trio -processing, presentation, and recognition -represent three significant criteria that a TAA must meet in order to be effective. Several peptides derived from hTERT are thought to be naturally processed by tumor cells, presented in an MHC class I-restricted fashion, and serve as a target for antigen-specific CTL (Vonderheide et al. 1999) (Table 1 ). The first hTERT peptide described, I540 (ILAKFLHWL), is a dominant epitope found within the middle of the deduced amino acid sequence of hTERT, approximately 70 amino acids to the amino terminus of the first reverse transcriptase motif. Discovered via epitope deduction, I540 is restricted to the MHC class I allele human leukocyte antigen (HLA)-A*0201 (HLA-A2), which is the most frequently expressed MHC class I allele (found among nearly 50% of Caucasians, Asians, and Hispanics as well as 33% of African-Americans). The peptide has been shown experimentally to bind strongly to HLA-A2 and generate from >70% of individuals CTL specific for I540 peptide that are able to kill hTERT-positive tumor cell lines and primary tumors from a wide variety of malignancies in a peptide-specific, MHC-restricted fashion (Vonderheide et al. 1999) . In addition to I540, other dominant hTERT-derived CTL epitopes that are restricted to other common MHC class I alleles have been described. The peptide K973 (KLFGVLRLK) binds strongly to HLA-A3 and triggers MHC-restricted CTL lysis of hTERT-positive tumors from a range of histologies (Vonderheide et al. 2001b) . Peptides restricted to HLA-A24 have also been identified (Arai et al. 2001) .
Natural processing and presentation of I540 is suggested based on the cytolysis of the HLA-A2 + , telomerase-negative sarcoma cell line U2OS only after retroviral infection with full-length hTERT but not vector alone. Monoclonal antibodies against HLA-A2 blocked cytolysis of hTERTinfected U2OS by CTL (Vonderheide et al. 1999) . Analysis via tetrameric complexes of MHC class I and peptide in flow cytometry identified a 1-3% population of tetramer-positive CD8 + cells among ex vivo expanded CTL (Vonderheide et al. 2001a 
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with I540 and these cells could recognize HLA-A2 + cells pulsed with I540 peptide or transiently transfected with the minimal epitope (Ayyoub et al. 2001) . However, I540 peptide-CTL failed to recognize wild-type telomerase-positive tumor cells and in vitro proteasome digestion of hTERT failed to produce I540, suggesting ineffective antigen presentation due to improper processing of I540 (Ayyoub et al. 2001; Speiser et al. 2002) . On the other hand, other groups have independently confirmed that I540-specific CTL are able to lyse hTERT-loaded target cells in a HLA-restricted, hTERT-specific manner (Minev et al. 2000) . Additionally, high affinity hTERT specific antibodies were generated via a phage antibody library and shown to bind to I540 peptide expressed on the cell surface of tumor cells, providing further evidence that hTERT epitopes are being effectively processed and presented on the surface of tumor cells (Lev et al. 2002) . Finally, TERT RNA-transfected dendritic cells (DC) used to vaccinate mice led to the production of CTL that could lyse melanoma and thymoma cancer cells as well as inhibit growth of three other tumors in mice of different genetic backgrounds (Nair et al. 2000) .
Cryptic epitopes as a means of addressing the issue of tolerance
Most of the currently described hTERT CTL epitopes are dominant as defined by their high affinity and stable interactions with MHC class I molecules. While such interactions lead to the generation of a robust immune response, dominant epitopes can also stimulate tolerance due to their high affinity and stability. Cryptic epitopes, defined by their low affinity and unstable interactions with MHC class I molecules, have also been explored as possible hTERT-derived tumor antigens because T-cells reactive with these epitopes may more likely escape tolerance induction. Traditionally thought of as poorly immunogenic, cryptic epitopes can induce a prominent CTL response after 'heteroclitic' modification, for example, changing position 1 to tyrosine (P1Y variants). This substitution increases binding of MHC and peptide, leading to the generation of CTL, in contrast to wild-type cryptic peptide, which fails to induce CTL. While cryptic epitopes possess low affinity and have unstable interaction with MHC molecules, properties that prevent them from being able to prime a CTL response, they are thought to be expressed at a high enough level physiologically by tumor cells to serve as target epitopes for effector CTL.
P1Y variants of naturally occurring and processed cryptic hTERT epitopes generate CTL that lyse malignant cells of various histologies in a MHC-restricted and hTERT specific manner and can be used to induce anti-tumor lymphocytes in peptide vaccinated mice (Scardino et al. 2002) . In mice, a head-to-head comparison of dominant and P1Y variants of cryptic epitopes demonstrated that the latter protect mice against a lethal challenge with an mTERT-expressing tumor while high affinity and more stable dominant epitopes did not (Gross et al. 2004 ). The failure of dominant epitopes to protect efficiently against tumor challenge was hypothesized to be due to the selective in vivo purging of high avidity CTL from the T-lymphocyte repertoire. Therefore, CTL induced by dominant epitopes are of lower avidity. Such purging does not occur with P1Y heteroclitic variants, likely due to insufficient presentation and deletion in the thymus, and thus a stronger CTL response is generated.
While cryptic epitopes represent an area for future antigen discovery, dominant epitopes have been used both in vitro and in vivo to induce specific CTL in humans. For example, hTERT-specific CTL have been generated ex vivo from cancer patients in multiple experimental systems. CTL against hTERT were equivalently induced ex vivo from cancer patients and normal volunteers, with CTL from each donor type labeling brightly with peptide/MHC tetramers and efficiently killing hTERT-positive tumor cells in an MHC-restricted fashion (Vonderheide et al. 2001a ). In another experimental approach, hTERT-specific CTL were generated ex vivo from cancer patients using autologous DC transduced with hTERT mRNA as the stimulating antigen presenting cell (Nair et al. 2000) . These CTL were shown to lyse primary human tumors in an antigen-specific fashion. Finally, Vieweg and colleagues have generated polyclonal anti-tumor CTL ex vivo from patients with prostate or renal cell carcinoma following stimulation with autologous DC transduced with whole tumor mRNA (Heiser et al. 2001a, b) . These CTL, as designed, had multiple antigen specifici-ties, a significant portion of which was against hTERT (Heiser et al. 2001a, b) . These results suggest that dominant epitopes are not inducing tolerance and subsequent purging of high avidity CTL to such a degree that a strong anti-tumor CTL response cannot be generated.
CD4 + T-cell generation
In addition to CTL, an effective anti-tumor response is dependent upon the generation of CD4 + T-lymphocytes. CD4 + T-cells play a prominent role in generation, maintenance, and regulation of CTL response, particularly the long-term or memory response against tumors (reviewed in Hung et al. 1998 ). CD4
+ T-cells have also been described to have direct anti-tumor effects via cytokine secretion. Recent work by Janssen et al. (2003) demonstrates that CD4 + cells are indispensable during the priming event of CTL, if secondary expansion against an antigen is desired. Such a long-term response would be a key component of any effective anti-tumor vaccine, and therefore the expression and discovery of CD4 + epitopes from TAA is of key significance.
hTERT epitopes for CD4 + cells have been elucidated via epitope deduction (Table 1) . Naturally processed MHC class II-restricted epitope R672 (RPGLLGASVLGLDDI) generated specific CD4 + T-cells that can respond via cytokine production to natural hTERT antigens from a variety of malignancies including prostate cancer, breast cancer, melanoma, and leukemia (Schroers et al. 2002) . Additionally, no cytokine production was observed in response to autologous hTERT-positive B-cells (Schroers et al. 2002) , suggesting perhaps a low potential of B-cell specific autoimmunity. More recent work has demonstrated that R672 and another described MHC class IIrestricted epitope, L766 (LTDLQPYMRQF-VAHL), are promiscuous and capable of inducing CD4 + response in the context of several different MHC class II types including HLA-DR1, -DR7, and -DR15 for R672 and HLA-DR4, -DR11, and -DR15 for L766 (Schroers et al. 2003) . L766 is naturally processed and presented, and recognized by the T-cell repertoire in healthy people and prostate cancer patients. This peptide induces antigen-specific responses to a variety of malignancies and was used to vaccinate humanized HLA-DR4 transgenic mice (Schoers et al. 2003) .
hTERT immunotherapy clinical trials-early returns and future promise A number of phase I clinical trials utilizing hTERT as a TAA have been recently completed with promising results and others are ongoing. All trials had or have the primary endpoint of establishing safety of approach and dosage.
In one of the trials, completed at the Dana-Farber Cancer Institute, seven HLA-A2 + patients with hormone-refractory metastatic prostate cancer or chemotherapy resistant metastatic breast cancer were given 34 vaccinations of autologous intermediately differentiated DC incubated ex vivo with I540 hTERT CTL dominant peptide and, as an adjuvant, keyhole limpet hemocyanin (KLH). No grade 3 or 4 adverse events were observed with an inoculating dose of 15 · 10 6 peptide-pulsed DC/vaccination except for one patient with tumor pain related to spinal cord progression one week after the first vaccine ). Due to the need for repetitive leukophoresis, escalation to the second (30 · 10 6 DC/vaccination) and third (90 · 10 6 DC/vaccination) dose levels were not performed. Because hTERT is normally expressed by CD34 + hematopoietic progenitor cells and activated B-lymphocytes, bone marrow aspirates, serum immunoglobulin levels, and absolute B-lymphocyte counts were performed to assess potential auto-immune effects and no significant changes were observed . hTERT specific T-lymphocytes were induced in 4 of 7 patients after multiple rounds of vaccination. Induced CTL were capable of killing tumor cells in vitro in a MHC-restricted fashion after sorting and polyclonal expansion, and partial tumor regression was observed in one patient post-vaccination that was associated with the presence of tumor infiltrating lymphocytes , suggesting that I540 was capable of inducing an tumor-lytic immune response. In another study ongoing at the University of Pennsylvania Abramson Cancer Center, patients with advanced breast cancer were vaccinated subcutaneously with I540 peptide emulsified in adjuvant with GM-CSF (schema in Figure 1 ). Among 10 patients treated thus far at the first or second dose level, no treatment-related serious adverse events have been observed. Injection site reactions and tumor pain following I540 peptide vaccination have occurred (in contrast to our first trial). In one patient, tumor infiltrating lymphocytes associated with marked tumor necrosis have been observed after vaccination (unpublished observations). Based on flow cytometric tetramer analyses, 7-10% of infiltrating CD8 + T-cells were specific for hTERT I540 peptide after vaccination and were persistent for 7+ months (unpublished observations). These results suggest that telomerase can serve as a tumor rejection antigen.
In an ongoing trial at Duke University, 12 patients with hormone-refractory prostate cancer were vaccinated weekly with 1 · 10 6 DC loaded with RNA encoding a chimeric hTERT/LAMP to allow for simultaneous priming of CD4 + and CD8 + T-cells or DC loaded with hTERT RNA alone. No toxicities have been reported, and induction of both CD4 + and CD8 + T-cells were observed (Su et al. 2003a ). Higher levels of hTERT-specific CD4 + T-cells and CTL with higher lytic activity were induced in patients who received DC transfected with chimeric hTERT/ LAMP RNA versus those who received DC with hTERT RNA (Su et al. 2003a ). These results suggest that CD4 + cells augment anti-tumor responses even in the primary response stage and encourage further exploration of simultaneous activation of CD4 + and CD8 + T-cells. Interestingly, this same group vaccinated 10 patients with renal cell carcinoma using total tumor RNA (Su et al. 2003b) . No dose-related toxicities or vaccinerelated side effects, including auto-immunity, were reported, while 6 of 7 patients underwent an expansion of tumor-specific T-lymphocytes. Vaccine-induced CTL were reactive against a variety of renal cell carcinoma antigens, including hTERT.
Another phase I effort in Norway has also attempted to generate both CD4 + and CD8 + hTERT-specific T-cells. A total of 505 vaccinations were given to 77 patients with non-resectable pancreatic cancer (47 patients), malignant melanoma (10 patients), and non-small cell lung cancer (20 patients). No serious adverse events and a correlation between vaccine dose, number of responders, and survival in pancreatic cancer patients was reported (Gaudernack et al. 2003) . Overall, these five studies present promise for the future of hTERT as a target for universal cancer immunotherapy. Low toxicities with data suggesting the potential for causing tumor regression support the rationale of hTERT as a tumor rejection antigen. Phase II clinical trials are currently being conducted to better ascertain the effectiveness of using hTERT to cause tumor death and regression. This is an open-label, dose-escalation phase I trial for patients with advanced breast cancer to determine the safety and immunogenicity of vaccinating patients with increasing doses of hTERT peptide. Eligible HLA-A2+ patients with advanced breast cancer are injected with 10, 100, or 1000 lg of hTERT peptide I540 emulsified in the adjuvant Montanide ISA 51 and delivered subcutaneously in the right thigh (Right). Patients are additionally vaccinated with 10, 100, or 1000 lg of CMV peptide N495 (an important control for patient immunological response) in the left thigh (Left). GM-CSF (70 lg · 1) is given subcutaneously at each peptide injection site. The protocol permits 8 vaccinations over 27 weeks. A minimum of 5 and a maximum of 8 patients will be treated at each of the three dose levels, depending on toxicity, in a standard clinical trial design. The maximum tolerated dose (MTD) will be defined as the highest dose for which fewer than 2 patients develop a significant treatment-related toxicity. Additional patients will be treated at the MTD so that a total of 12 patients will have been treated at the MTD. If 12 patients are treated at the MTD and 8 patients are treated at each of the other two doses, a maximum of 28 patients will be enrolled.
Summary
The future for hTERT as a universal tumor rejection antigen looks bright. In vitro and in vivo work demonstrates that hTERT meets all the criteria of a tumor associated antigen: widely expressed in a tumor-specific manner, naturally and effectively processed and presented antigens in the context of MHC class I molecules, and recognition by the available T-cell repertoire present in both normal and cancer patients. Additionally, hTERT's role in preventing tumor cell senescence suggests malignancies would be unable to downregulate hTERT expression or telomerase activity in response to the selective pressure of hTERT based immunotherapy. The presence of numerous dominant and variant cryptic epitopes of different HLA alleles that are capable of inducing CTL and CD4 + T-lymphocytes provide several options for vaccine-based therapy and potential for future epitope discovery. Completed and ongoing clinical trials have demonstrated that hTERT-specific CTL alone as well as in combination with hTERTspecific CD4 + lymphocytes can be generated via a cancer vaccine approach with no serious autoimmune or toxic side effects, including bone marrow and immune function. While hTERTs effectiveness in inducing tumor regression will be further assessed in phase II clinical trials, initial results from phase I trials suggests that regression and rejection is possible due to the observation of tumor necrosis associated with the presence of tumor infiltrating lymphocytes in some patients.
